EU wants to withdraw all dextropropoxyphene products
This article was originally published in Scrip
All marketing authorisations for dextropropoxyphene-containing products should be withdrawn in the EU because of the risk of intentional or accidental overdose, the EU's CHMP has recommended. The risk of overdosing only became evident when data from national poison centres and mortality statistics throughout the EU were analysed in depth, the committee adds.
You may also be interested in...
Canada’s Aurinia Pharmaceuticals expects to file a US NDA in the first half of next year on the use of its next-generation calcineurin inhibitor, voclosporin, in lupus nephritis, a condition with no approved therapies.
The first part of Aldeyra’s Phase III RENEW study of the aldehyde trap candidate, reproxalap, shows positive effects on one of two co-primary endpoints and indicates an induction-maintenance dosing regimen should be used in part 2 of the study, expected to start in the first half of next year.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.